Thank you, and thank you all for joining us for today's earning call.
This call is being webcast live on our website, ir.navidea.com and a replay will be made available.
Following prepared remarks, we will be conducting a live Q&A session.
Finance the Erika call of joining will President on me today. Vice and Eves Administration, be Navidea’s
COVID-XX During the the course our be the making of These business this conference statements company. Navidea’s future call, plans regarding along business as include and strategic resources to clinical which events molecular relate and the immunotherapeutics, and capital events future of regulatory developments Navidea’s timing as with well develop pandemic of of and forward-looking performance and clinical to operations. we impact the diagnostics data on readouts, matters will
assume statements on Investors could obligation factors as and certain update let’s or otherwise. within website All carefully new are or our the of risk the whether to of the events statements now, the risks expectations annual SEC. assumptions, quarterly filings beliefs cause And update. Harbor with with management actual these a and risks described revise as today. involve section no Safe These future result statements based should of our company’s most included of We forward-looking and as the results uncertainties uncertainties and as recent to and of begin read information, in materially. well the differ
the financing continued XXXX for During first and on of have to the work quarter since, we company.
This XB the time, this that are but of and payment in as well can We trial and good we've but weeks be received release with non-fibroid and imaging comparing several and hope are to continue a detail, shareholder will Phase ago, on do our rheumatoid say I data another the funds distinguish so. on XX at press biopsy. of have of Scott, hypotheses the milestone capital. current of great terms support options results progress pursued Board expression These Kim I the in as will Directors, engagement working we potential we you Tilmanocept the upcoming. our banks our to able Erika the our CD-XXX our Overall, And payment all Mr. strong from patients provide due biomarker the arthritis, to assured Vice from being and highlighting continually, as made investment we is largest updates imaging as we with saw you in pathotype we results ability joints our early multiple patients. bridge small are company's cover promising financials Chair and provide support in RA. and with of fibroid have evaluated the of first loan a
up the We also X site. have continue to enroll recently and opened another Phase into RA
diligently various hard and group company in this management with be Board Senior of the and United and Additionally, we efficiently, I'm continues forward. the imaging outstanding are associated team the property. in institutions advancing and The relationships we across maintaining collaborative are well-known And moving growing and applications work of very with intellectual through to company's to works here are our the Directors closely extremely therapeutics with globe. investigators we proud individuals.
As recent as soon behind updates are are many there said scenes and we've the we we are able we with as provide in past, as things the you will working and appropriate. on
more Rheumatoid Arthritis provide the to I'll RA our like begin or updates. would I with in Now, progress detail around clinical program.
identify And reached based sites we're TNF an our to enroll alpha enrollment a indications selected patients on alpha carefully third to response patient now B RA, the with we're we've digits with Phase or early to them two, level a and into happy ground of opened III TNF prediction hit RA first they've the to new double anti localization respond running. to therapy. to who treatment So Phase are likely are that the less The site. and on low have up going anti first-time recently see for just in we II experience therapy, of one We've our continue trial and previous trial.
effects. there or the a therapies lead unnecessary for have we with treated early term a reliable being RA, previously, that patient's need large therapy possible not along working, can bring unmet costs long patient consequences discussed a with working disease of with predictor not this because a ineffective is drug for drug is As is in if and not high to them is health side whether
predictor of RA been in in have have imaging with early imaging conducted place, alpha that Phase and Our more our site up unmet to switching Tilmanocept hit addressing of we the remains to contracts we in NAV gas visits site III therapy, an negotiating recruitment. ability number in biopsy of a sites, as opening. response sites we Once in funding our lining to of that preparation dozens really TNF we open the can have and many medical serve patients for the up trial joint an qualification active have that sites we treatment need. XXX comparison for establish will Tilmanocept study been prepare to of literally large anti
trial were As preliminary announced discussed of and recently, promising. we've results the this
a of is imaging of of we pathology designed pathotypes to And the pathotypes fibroid, diffuse is each three that of and myeloid, of subjects aim RA RA, recruit lympho-myeloid. trial to Our the and obtain comparative the in the the minimum each enroll so four patients three with results.
biopsies the imaging one scheduled completed for to queue. we XX, in size both trial of Out fibroid, and and XX week, between diffuse the To have three been seven joint overall have have had So next and has others and patient imaging range who another we date, XX expected completed myeloid, XX. their patients lympho-myeloid.
pathotype in no patient currently of is to what other RA there Importantly, biopsy. via a has know way than advance
the There's values RA of pathobiology relationship joints. enrollment enroll. between assess uptake the is to who The pathotype joint are willing be may primary eligible likely it of growing Knowledge suggesting specific individual to study responsive So on clinically less important those are body this involved Tilmanocept a TNF which of of those of RA may much subtype respond. the RA the and patient RA than with subtypes. other therapy alpha an because is predict fibroid patient's literature our patients objective anti a to based the to and to drugs that is
as And not in opinion means important particular or key pathotype a determining so Rheumatology. of is this a whether patient leaders of extremely a number to has seen
time, way Tilmanocept this imaging of information. biopsy. a provide than mentioned, hypothesized reliable just I as a by RA we have of could that patient's doing is As other there this of the pathotype no assessing And
who results those patients in low that macrophage from able differentiate preliminary XX is on with first fibroid either Tilmanocept those to the discreetly So having those uptake the involvement pathotype, of involvement. joints myeloid higher those indicate RA with RA, or diffuse pathotypes macrophage have patients lympho-myeloid inflamed
subjects had low out of the SPECT imaging. the and of than with three or on SPECT average myeloid Those All as subjects seven one TNFα lympho myeloid remaining fibroid times the with more three those out subject myeloid So the four either pathotype myeloid, diffuse subjects the imaging relatively of tilmanocept had subjects, of the seven average, seven pathotypes pathotype. of found seven, had of levels diffuse the were pathotypes. fibroid the lympho the
to likely TNFα fibroid the if able is Phase or has as baseline uptake the type XX our patient we ability for the anti benefit path are a have of also therapy. based the scan an in TNFα higher likely clinical those I the So RA, results all indications to from imaging predict clearly all taken whether To in they provide before is of on fibroid from fibroid X receive as either to date, mentioned, than a biopsy one these there patients. data a from been benefit a patients of had less namely, classify significant to then our non-fibroid meaningful clinical cases, Since, support receive evidence that patient trial, alone, increasing anti therapy. subjects
looking of anti in Those baseline to at exhibited gold clinical treatment pilot XB the an previously their level Phase TNFα low joints in rate almost who efficacy using response. imaging might contained XX% scan TNFα on therapy had patients study standard completed TNFα our a that imaging the SPECT You prediction assessments. early of non-response recall SPECT arm a at their
are is several at trials sites recruiting, number but faster expected what biopsy as times operations expectations. done exceeding notoriously these great slow fact, Finally, in job lead of a our over principal our clinical usual. our team rate -- has than would've recruitment here The indicated investigator
We'll screening patient another week, about more several several have I screening next the on in the or keep in imaging progress. next scheduled, you posted We for over mentioned discussions weeks. as
for as product. the on progress automating We will continue to make have benefit the well, quantification which very significant image good commercial
are sensitive Keep serves upon the which the us you've all critical but continue data to reads the read use ability to agreement This an critical pilot We possible commercial but on a at scale of partnership next a they can proprietary tilmanocept the is NIM through and RA. reads finalize NIM when space. Once we're company There as rapidly We'll it trials, an with images, that is is as of automated a medicine barrier closely SPECT the our deriving and methodology, large is heard for analysis tilmanocept study the consider be our make a completed reproducably, a and them our of of SPECT this, have again, to months. most of to goal the quantitative using we'll terms in discuss footprint develop scale perform large software can partner means built, from RA. using this demonstrating it have our of quantitative nuclear of fully large space. RA our the and we in well that to based quantification commercial significant work in the will it competitors as with not accurate to imaging couple many our only rollout working important to announcement that data intent algorithm. factors for normative imaging agreement, for also be reproduce full completed the Cleveland robustly work NIM to done. letter the to database entry software automated for to medical is mind application as imaging, before product, of leading are with in imaging image objective the within They a including and through
is secondary effect. in released the potential analysis on updated also great the validate leading MOU, from and report results market market The the primary for regarding valuation input We need if assumptions that it exclusivity include research this and our available period RA, are of our recently value product the U.S. approved, is still European The Jubilant rheumatologists website. and for, and States. product of our across potential United RA and
As NAVX-XX for in we and beginning. to important continue have mentioned in the both the since have been their have and biopsy study discussions I the us milestone of and completion leadership these involved in Jubilant. with communication the been be an past, is
up keeping the them results. and We on to are date progress study NAVX-XX
we program increasing and asset, program. our long in not as our of And we position. As hypotheses, our but remains as also value advance the only clinical are our data supportive de-risking
several presented the the localization is in the February When study. we're co know. study submitted imaging been at you in plaque terms of published manuscript investigator in on ago. mass MGH of plaque accepted, on in international sites manuscript Boston, study our a let will conference initiated have in disease cardiovascular promising an The was based tilmanocept have data, general pilot On line results. that them with the full with front, atherosclerotic reported abstract and We what and completed group we hospital of -- an the years at at
anti-inflammatory therapeutic extramural the preclinical agents at progressed at and of tilmanocept Navidea through advancing collaboration and our studies PET for have and Alabama in researchers and imaging the candidates front, the related assets or next-generation Gallium internal On with through XX significantly Birmingham are Pre-clinical oncology UAB. imaging we University Manocept at spaces. work
our new accepted been has by can significantly the preclinical we tilmanocept NIH-funded to a studies in increase model tilmanocept meeting tilmanocept agent has a work off for designed site at injection. to new was target imaging agent showing successful a and the liver. another tissues, increase and administered to similar is our off a set evaluating tilmanocept like localization target dramatically This studies imaging to in while submitted Gallium technology blocking to when well. pre-clinical designed have XX to looked were imaging target intravenous of an of block as important liver, very that localization of agents studies atherosclerosis. manuscript Work localization We on the imaging was These localization while of agent localization new technology to an international imaging completed and second a abstract completed which work to tumors, various on of been at mouse a simultaneously major
Additional status and beneficially example, has be progressed. new work immune cancer for constructs rate models drug, new also reduce of on alone significantly that the altering in combination for delivery with the macrophages constructs of and tumor that new These carry may growth. when have drug doxorubicin than payloads effective tumor targeted drug results new payloads mouse administered constructs these another demonstrated therapeutic or more
reach allowed should presented details a results at meeting be will. soon to Some are well. therapeutics cancer we of as we When release these
product. macrophages. the It that a a countries infected priority tropics, of ISIS. recipient received new list for parasite review where of on Because US, tropical is are we replicates to otherwise It's a protozoan caused for vouchers would development for Southern low a the to the recently rare neglected review life-threatening it's vouchers U.S. based found treatments companies through and to FDA have is new but developed. the of eligible the a serious, from sold disease allow PTO a from the and application therapeutic this more expedite Europe. be that classified is of the not and that situation by have are transmitted announced the as million as also to in sandfly in is sandfly Leashman CD-XXX subtropics man These Leashman a can positive spur vector as of goal receive These to Leishmaniasis vectors notice other the to borne our dollar hundreds that disease. common FDA's by disease. chronic figures dollars. XX millions voucher. allowance tropical tropical a patent ranged It bite of diseases diseases found, of humans of issued in is We of be potentially ISIS covering The in drug parts
with in this high world have have have preclinical Leishmaniasis, recently the of earlier the work that expressing results. renewed preclinical So play underway. study of is the back form we early in a macrophages currently published disease. follow-on to XXXX, in we demonstrating role dominant promising CDXXX more studies and one A And leaders area
of As awarding review further our the is these the extremely of reveals as This for significant strategy. updated. studies important progress, constructs value our Navidea. as our we Leishmaniasis, have will keep voucher you well potential therapeutic treating If a priority research more supports and technology of of could the platform efficacy economic for
robust brings is overall And That so moving pipeline forward. our our therapeutic property me intellectual front. and to
provisionals. In should conceived days several the in new works Two provisional new we in submit till in submitted the pending to go months, Xst, last applications. quarter another two November weeks. up since now our the have have continue work We that last out and coming and applications and and on six the
chemotherapeutics The of first new recently man for and of indications. second tissue maximizing platform. implications the off filed to important those to blocking. methods target have to And competitive related These is pipeline the target step relates attaching uptake
claims have allowed update on in you call countries. see As applications various on can patent had release, we press also earnings today's different
generation that provide our protection disease indications. and molecules needed IP have to agents, diagnostic to both We well our will as rights an protections as and therapeutic strategy and active we current believe next
press of in also as aim recently We approval regulatory lymphocy release India. the lympho
there. as milestone this completion quarter. due first will patients release, lead a the India, We're of process, need. will license. of expect as regulatory of our received that has upon due regulatory that Sayre delighted payment to is India for end the Therapeutics the small inquiry aim by available payment in another import the partner mentioned application well in approval receipt efforts We'd that be lympho and in commercialization As There in
update. these to while the largely other to progress remain the pipeline, on our of continue for wanted Phase highlights imaging biopsy II for quarter B We this the touch the focused So last we on we III, just trial some to and and on support and specifically of are diagnostic therapeutic that push the RA Phase indications.
to hard Eves. want And you. Erika? here work. collaborators the to move that, introduce moving I tireless on I'll of for and team Erika all clinical always, And thank let's to now, their with As things trial keep their our sites network of research for financial updates. efforts the Thank and academic
